Oncolytics Biotech Inc. (TSE:ONC – Get Free Report)’s stock price hit a new 52-week low on Friday . The company traded as low as C$0.86 and last traded at C$0.88, with a volume of 6500 shares traded. The stock had previously closed at C$0.90.
Oncolytics Biotech Price Performance
The company’s 50-day simple moving average is C$1.02 and its 200-day simple moving average is C$1.27. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The company has a market capitalization of C$66.28 million, a PE ratio of -2.40 and a beta of 1.35.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Read More
- Five stocks we like better than Oncolytics Biotech
- Pros And Cons Of Monthly Dividend Stocks
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- How to Profit From Value Investing
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- 3 Tickers Leading a Meme Stock Revival
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
